Welcome to our dedicated page for Acadia Healthcare Company SEC filings (Ticker: ACHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Acadia Healthcare Company's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Acadia Healthcare Company's regulatory disclosures and financial reporting.
Acadia Healthcare Company, Inc. Schedule 13G/A reports that Wellington Management entities together beneficially own 9,072,942 shares of Acadia common stock, representing 9.86% of the class. The filing lists shared voting and dispositive powers across related Wellington entities and identifies underlying adviser-client record ownership.
Acadia Healthcare Company, Inc. disclosed the initial equity holdings of Interim CFO David M. Duckworth in a Form 3 filing. The report shows he holds 750 shares of Common Stock directly, providing a baseline of his ownership but not recording any recent purchases or sales.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed an amendment to a Schedule 13G reporting shared voting and shared dispositive power in ACADIA HEALTHCARE COMPANY, INC. The cover data shows shared voting power of 1,453,488.72 shares, shared dispositive power of 1,454,430.72 shares and a reported total of 1,464,125.72 shares representing 1.6% of the class as of 03/31/2026. The filing is a joint filing under a Joint Filing Agreement signed by Sam Prashanth on 04/24/2026.
Fucci Michael reported acquisition or exercise transactions in this Form 4 filing.
Acadia Healthcare Company, Inc. director Michael Fucci received a grant of 6,331 shares of common stock as compensation. The shares were awarded at no cash cost to him and will vest over a three-year period in equal yearly installments beginning on May 6, 2027. After this grant, he directly holds a total of 28,152 shares of Acadia Healthcare common stock. This is a routine equity award rather than an open-market purchase or sale.
Acadia Healthcare Company, Inc. director Ralph David Kelly received a grant of 6,331 shares of Common Stock on May 6, 2026. The award carries no cash purchase price and represents a grant, award, or other acquisition of shares. These shares will vest over three years in equal yearly installments beginning May 6, 2027. Following this grant, Kelly directly holds 26,358 shares of Acadia Healthcare common stock.
Gregg Vicky B reported acquisition or exercise transactions in this Form 4 filing.
Acadia Healthcare Company, Inc. director Vicky B. Gregg reported receiving a stock award of 6,331 shares of common stock on May 6, 2026. The grant was at no cash cost per share and increased her direct holdings to 42,628 shares after the transaction. According to the filing, these awarded shares will vest over three years in equal yearly installments beginning May 6, 2027, meaning portions of the grant become available gradually rather than all at once.
Bernhard Jason reported acquisition or exercise transactions in this Form 4 filing.
Acadia Healthcare Company, Inc. director Jason Bernhard reported two stock awards of common stock on May 6, 2026. The filings show grants of 5,124 shares and 6,331 shares at a stated price of $0.00 per share, indicating compensation awards rather than open-market purchases.
Footnotes explain that the shares will vest over a three-year period in equal yearly installments beginning May 6, 2027, and that one award reflects Mr. Bernhard’s election to receive his 2026 annual cash retainer as a director in shares of common stock.
GRIECO WILLIAM reported acquisition or exercise transactions in this Form 4 filing.
Acadia Healthcare Company, Inc. director William Grieco received an equity grant of 6,331 shares of Common Stock as compensation. The shares were awarded at no cash cost to him and increase his directly held stake to 96,212 shares.
The granted shares will vest over three years in equal yearly installments beginning on May 6, 2027, meaning he earns the shares gradually over time as service continues on the board.
Cancelmi Daniel J reported acquisition or exercise transactions in this Form 4 filing.
Acadia Healthcare Company, Inc. director Daniel J. Cancelmi received a grant of 6,331 shares of common stock as reported on a Form 4. The award carried a stated price of $0.00 per share and is compensation-related rather than an open-market purchase or sale.
According to the disclosure, these shares will vest over a three-year period in equal annual installments beginning on May 6, 2027. Following this grant, Cancelmi directly holds a total of 12,956 Acadia Healthcare common shares, reflecting his updated equity stake as a company director.
Harris Patrice A reported acquisition or exercise transactions in this Form 4 filing.
Acadia Healthcare Company, Inc. director Patrice A. Harris reported receiving a grant of 6,331 shares of Common Stock as compensation. The award was recorded at a price of $0.00 per share and increased her directly held stake to 17,914 shares.
The granted shares will vest over three years in equal yearly installments beginning on May 6, 2027, meaning the award is subject to continued service or other vesting conditions rather than being fully owned immediately. This filing reflects a routine equity compensation grant, not an open-market purchase or sale.